Keynote Address: New approaches for treating dysregulated adaptive immunity
Jo Viney, PhD, Co-Founder, President, CEO, Seismic Therapeutic
Session I:
Clinical development of IL-23 inhibitors: From mAb monotherapies to combo and novel orals
Co-Chairs: Heidi Feldser & Siquan Sun
- Advancements in IL-23 in Health & Disease: from Research to Clinical Development of IL-23 Inhibitors
- Heidi Feldser, GlaxoSmithKline
- Molecular Differentiation of Anti-IL-23 Therapeutics
- Kacey Sachen, Janssen R&D
- From the Laboratory to the Clinic: Anti-TNF and Anti-IL-23 Combination Therapy in Inflammatory Bowel Disease
- Leon Chang, Janssen R&D
- First-in-Class Oral Peptide Systemically Targeting the IL-23 Pathway
- Anne Fourie, Janssen R&D
Session II:
New frontiers in systems immunology: how new technologies and AI can guide therapeutic discovery & development
Co-Chairs: Arpita Maiti and Dale Wright
- Mapping and Navigating Biology and Chemistry at a Genome Scale
- Marissa Saunders, Recursion Pharma
- Targeting RNA with small molecules – Lessons from mapping the druggable transcriptome
- Tim Allen, Head of Chem AI, Serna Bio
- Spatial Transcriptomics of Hidradenitis Suppurativa Tissue Reveals Disease Biology
- Kathleen M. Smith, Immunology Computational Biology, AbbVie Discovery
- Immune System Modeling to Drive Key Pharma R&D Decisions
- Liza Aizman, Senior Director of Science Operations, CytoReason
Session III:
Translational research and innovative technologies
Co-Chairs: Xiaofeng Yang and John Armstrong
- Single cell RNA-Seq for inflammation research
- Professor Ying H. Shen, MD, PhD at Baylor College of Medicine
- Inflammation triggered tissue remodeling and novel therapeutics
- Professor Roberto Vazquez-Padron, PhD, University of Miami
- Mass spectrometry based approaches to blood based marker detection for Oncology
- Colin McDowell, PhD, Biodesix
- A.I. for Drug Development in Immune-Mediated Inflammatory Disorders
- John Armstrong, PhD, President, JAV, LLC
Session IV:
New Approaches to Treat Autoimmune Diseases by Promoting Tolerance
Co-Chairs: Lisa Schopf and Fridrik Karlsson
- Ligand-non-competitive blocking of TNFRSFs for treatment of autoimmune diseases
- Fridrik Karlsson, Pfizer
- Restoration of Immune Balance with Immune Checkpoint Modulation: A New Treatment Paradigm
- Cailin Sibley, MD; Vice President Translational Medicine, AnaptysBio
- (neo)Antigen-specific immunotherapy for autoimmune diabetes
- James DiLisio, M.S., Graduate Student, Haskins lab, University of Colorado Anschutz Medical Campus
- Open Panel Discussion: 30 minutes
- Suggested topics for the panel discussion may include new antigen-specific tolerance promoting therapeutic vaccines, Treg-promoting cytokines, CAR-Tregs and checkpoint receptor agonists.
Session V:
Selected Poster Abstracts
Co-Chairs: Sharlene Velichko and Caitlin Parello
https://inflammationresearch.org/2023-abstract-submission
- SIGMAR1 is a Novel Onco-Immunological Biomarker Regulating PD-L1 Expression in Human Oral Cancer
- Pablo Shimaoka Chagas, University of Sao Paolo and Augusta University
- Neutralizing antibodies suggest C-C motif chemokine receptor-like 2 (CCRL2) ligand binding function is dispensable for neutrophil responses to CXCL8
- Joseph Brennan, Pfizer
- Colitis Development in Germ-Free IL-10 Deficient Mice Inoculated with Murine FMT
- Caitlin Parello, PhD, Biomodels, LLC
Session VI:
Early Discovery Strategies in Inflammation: Mechanisms, Targets and Approaches
Chair: Liwu Li
- Innate immune memory dynamics and therapeutics
- Liwu Li, PhD, Professor of Virginia Tech
- Human Genetics Based Drug Discovery and Development
- Clarissa Lee, PhD (23 & Me)
- Trained immunity and inflammation enhancement
- Xiaofeng Yang, PhD, Professor Temple University
- Drugging the Undruggable
- Paul Smith, PhD (Recludix)
Session VII:
Meet the Professional Networking Session
Moderator: Lisa Marshall
Click HERE for Session Expectations & Additional Resources.
- Welcome and Introduction
- Lisa Marshall (5 Min)
- Networking the Key to Career Development
- Chase Weldon, CSU (20 min)
- Speed Networking
- Caitlin Parello, Nicole Smith (60 min)
- Meet the Professional: Panel Discussion
- Lisa Marshall (30 Min)
Session VIII:
Inflammation and Disease: Patient Perspectives
Co-Chairs: Heather Jones and Ana Biljan
Disease Area:
- Inhibitory signaling mechanisms in B cells: critical for B cell tolerance and potential therapeutic targets to treat autoimmune disease
- Andrew Getahun, University of Colorado School of Medicine
- MD/APP – Clinician
- Patient Perspective
- Q & A
Session IX:
Inflammation and Pain: New Science and New Treatment Strategies
Chair: Dirk Smith
- Acute inflammation protects against the development of chronic pain
- Luda Diatchenko, McGill University
- Dermal macrophages set pain sensitivity
- Tatsuhide Tanaka, Nara Medical University
- B cell regulation of neuropathic pain
- Peter Grace, MD Anderson Cancer Center
- Q&A and roundtable
- Dirk Smith, moderator
Session X:
Emerging Therapeutic Strategies in Inflammation: New Drugs & Novel Clinical Approaches
Co-Chairs: Miguel Sanjuan and Xiao Hu
- AG019 ActoBiotics as Monotherapy or in Combination with Teplizumab in Recent-Onset T1D Was Safe and Demonstrated Encouraging Metabolic and Immunological Effects
- Pieter Rottiers, CEO, Precigen ActoBio
- Multiple-Dose-Escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of PRV-101, a Coxsackie Virus B (CVB) Vaccine, in Healthy Adult Subjects
- Miguel Sanjuan, Senior VP Research & Early Development at Provention Bio a Sanofi Company
- Identifying New IBD Drug Targets & Accompanying Patient Stratification Biomarkers from Large Multi-Modal Datasets
- Heather Llewellyn, Prometheus Biosciences, Inc.